Enzyme (threonine protease; component of the Ntn hydrolase family within the proteasome), Other (multisubunit proteolytic complex component; 20S proteasome core particle)
01
Overview
Proteasome subunit beta type-7 (PSMB7) is the constitutive β2 subunit of the 20S proteasome core particle, contributing the protease’s trypsin-like activity that cleaves after basic residues. The 20S core is a barrel of four stacked heptameric rings (α7–β7–β7–α7); three β subunits (β1, β2, β5) provide the N-terminal threonine active sites facing the inner chamber where proteolysis occurs. PSMB7 (β2) is incorporated into the two inner β rings and participates in ATP/ubiquitin-dependent protein degradation when the 20S core is capped by regulatory particles (e.g., 19S) and in ubiquitin-independent degradation when associated with PA28/PA200. In immune contexts, interferon-γ can favor replacement of β2 by the inducible β2i in immunoproteasomes, affecting peptide generation for MHC class I presentation.
Covalent or reversible inhibition of 20S proteasome catalytic sites within the β-ring, blocking proteolysis and leading to accumulation of ubiquitinated proteins, cell-cycle arrest, and apoptosis in malignant cells. Some inhibitors preferentially target β5 but can affect β1/β2 activities; β2 corresponds to trypsin-like activity contributed by PSMB7
03
Biological functions
Proteolysis of intracellular proteins (ubiquitin–proteasome system)Trypsin-like activity cleaving after basic residues (assigned to β2 site)Protein quality control and turnover of regulatory proteinsAntigen processing for MHC class I via proteasome/immunoproteasome pathwaysUbiquitin-independent degradation when 20S associates with PA28/PA200 regulators
04
Disease associations
Cancer (proteasome activity is essential for tumor cell survival; proteasome inhibitors are anticancer therapies targeting 20S catalytic activities)Infection/Immunity (role in antigen processing; interactions of proteasome system with viral processes described for proteasome subunits)Neurodegenerative disease (UPS dysfunction implicated broadly in neurodegeneration; proteasome function central to protein homeostasis)
05
Safety considerations
On-target toxicities from global proteasome inhibition: peripheral neuropathy, cytopenias, gastrointestinal effects, and cardiac effects reported with proteasome inhibitors due to inhibition of protein homeostasis in normal tissuesPotential immunomodulatory effects via altered antigen processing and cytokine responses
06
Interacting drugs
Bortezomib
2 more in the full profile.
07
Biomarkers
Proteasome activity signatures (chymotrypsin-like, trypsin-like, caspase-like activities) used to monitor pharmacodynamic effect of proteasome inhibitors in blood/tumor cellsImmunoproteasome/constitutive subunit expression balance (e.g., β2 vs β2i) can influence antigen processing and potentially drug sensitivity; IFN-γ downregulates β2 (PSMB7) with β2i replacement
Beyond the preview
Go deeper on Proteasome subunit beta type-7 (PSMB7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proteasome subunit beta type-7 (PSMB7).